What is Aclarion, Inc. (ACONW)?

Aclarion, Inc. (ACONW) is a stock in the Healthcare sector, Medical - Healthcare Information Services industry. View full analysis on Stocks360.

What is the current price of ACONW?

The current price of ACONW is $0.02. Prices are updated in real time on Stocks360.

What is ACONW's price-to-earnings (PE) ratio?

ACONW's trailing twelve-month PE ratio is -0.26, based on current price and earnings per share data available on Stocks360.

What is ACONW's market capitalization?

ACONW's market capitalization is $13,173.00, placing it in the small-cap tier.

Aclarion, Inc. (ACONW)

Stock analysis · NASDAQ · Healthcare · Medical - Healthcare Information Services

$0.02

Market Cap

$13.17K

PE (TTM)

-0.26

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.21

Day Range

$0.02 – $0.02

52-wk Range

$0.02 – $0.20

Avg Volume

N/A

Volume

150.00

Aclarion, Inc. (ACONW) is a publicly traded company in the Healthcare sector. Latest price: $0.02. Market cap $13.17K. Trailing PE -0.26. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 9 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $0.05 2026-10-30 · $0.02 (-46.30%)

Earnings

Most Recent

Aug 6, 2026

EPS $-1.12 vs est. $-1.05

Missed by $0.07

Next Earnings

Dec 2, 2026

EPS estimate $-1.15

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aclarion, Inc.

Aclarion, Inc. is a healthcare technology firm specializing in software development for magnetic resonance spectroscopy (MRS) within the U.S. market. Its flagship product is the NOCISCAN-LS Post-Processor suite. This comprehensive suite includes NOCICALC-LS, which processes magnetic resonance spectroscopy (MRS) data from spinal discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a vital clinical decision support tool. Initially named Nocimed, Inc., the company adopted the Aclarion, Inc. moniker in December 2021. Established in 2008, Aclarion, Inc. maintains its headquarters in San Mateo, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.26×
P/S (TTM)	67.10×
P/B	0.28×
P/FCF (TTM)	-0.70×
EV / EBITDA	1.19×
EV / Sales	-127.31×
Earnings Yield	-191.54%
Free Cash Flow Yield	-143.87%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$10.66M
Net Income (TTM)	-$10.77M
Free Cash Flow (TTM)	-$8.17M
Net Debt	-$16.29M
Working Capital	$15.76M
Gross Margin	-50.96%
Operating Margin	-11592.14%
Net Margin	-10978.48%
Return on Equity	-59.34%
Return on Invested Capital	-57.11%